Merck & Co licenses Japan Tobacco's novel osteoporitic
This article was originally published in Scrip
Executive Summary
Merck & Cohas acquired the global rights outside Japan to a novel compound for osteoporosis being developed by Japan Tobacco (JT). The move should help to shore up the US firm's franchise in this therapeutic area following the loss of exclusivity for Fosamax (alendronate) earlier this year.